Get started
Author

Fabricio Racca

Observed names: F. Racca, Fabricio Eugenio Racca, Racca, Fabricio
Observed institutions: Universitat Autònoma de Barcelona, Istituto Oncologico Veneto, Hospital Quirónsalud Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, IDCQ Hospitales y Sanidad, S.L.U.
ORCID: 0000-0002-1502-6989
Observed ORCID: 0000-0002-1502-6989
OpenAlex ID: A5016561440
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
2022 · José Manuel Pérez-García, Marta Vaz Batista, et al. · Neuro-Oncology · 261
PDF
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
2024 · Ignacio Melero, Maria de Miguel Luken, et al. · Nature · 157
PDF
Targeting FGFR pathway in breast cancer
2017 · J. Perez-Garcia, E. Muñoz-Couselo, et al. · The Breast · 112
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
2024 · Marta Vaz Batista, José Manuel Pérez-García, et al. · Med · 58
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
2023 · Glenn J. Hanna, Anastasios Stathis, et al. · Cancer Research Communications · 49
PDF
Clinical Implications of Extracellular HMGA1 in Breast Cancer
2019 · Olga Méndez, José Pérez, et al. · International Journal of Molecular Sciences · 35
PDF
Atezolizumab in the treatment of metastatic triple-negative breast cancer
2020 · José Pérez-García, Jesús Soberino, et al. · Expert Opinion on Biological Therapy · 29
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope
2016 · Rafael Morales-Barrera, Cristina Suárez, et al. · Cancer Treatment Reviews · 27
Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.
2021 · Elena Lopez Miranda, Anastasios Stathis, et al. · Journal of Clinical Oncology · 24
Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.
2021 · Raghad Muhsin Abdul-Karim, Arvind Chaudhry, et al. · Journal of Clinical Oncology · 10
SOLTI-1904 ACROPOLI TRIAL: Efficacy of Spartalizumab Monotherapy Across Tumor-Types Expressing High Levels of PD1 mRNA
2022 · Aleix Prat, Luis Paz-Ares, et al. · Future Oncology · 9
Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study
2022 · Marta Vaz Batista, Patricia Cortez, et al. · Cancer Research · 5
330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
2021 · M. Vaz Batista, J.M. Pérez-Garcia, et al. · Annals of Oncology · 4
Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: A case report
2018 · Karen Cort�s‑Mateus, Katarzyna Holub, et al. · Oncology Letters · 4
PDF
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial
2025 · E. Seguí, F. Brasó-Maristany, et al. · ESMO Open · 3
PDF
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
2025 · Aaron Richard Hansen, Alison Yan Zhang, et al. · Journal of Clinical Oncology · 3
Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm
2019 · Jesús Soberino, Fabricio Racca, et al. · Current Breast Cancer Reports · 3
Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).
2016 · Fabricio Eugenio Racca, Ester Zamora, et al. · Journal of Clinical Oncology · 3
Ip02-34 Treatment of Recurrent Non-muscle Invasive Bladder Cancer With Ugn-301 (zalifrelimab): Results of a Phase 1 Dose-escalation Study
2025 · Marco Maruzzo, Osvaldo Padron, et al. · The Journal of Urology · 2
PDF
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
2025 · Ignacio Melero, Maria de Miguel Luken, et al. · Nature · 2
604 Magrolimab + docetaxel in previously treated patients with metastatic non-small cell lung cancer (NSCLC)
2024 · Oscar Juan-Vidal, Bruno Fang, et al. · Journal for ImmunoTherapy of Cancer · 2
Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
2023 · Timothy A. Yap, Andres Cervantes, et al. · Cancer Research · 2
A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.
2026 · Omar Saavedra, Fabricio Racca, et al. · Journal of Clinical Oncology · 1
Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study.
2026 · Nobuaki Matsubara, Teresa Alonso Gordoa, et al. · Journal of Clinical Oncology · 1
A Phase 1 Dose-escalation Study of Ugn-301 (zalifrelimab) in Patients With Recurrent Non-muscle Invasive Bladder Cancer (nmibc)
2025 · Marco Maruzzo, Osvaldo Padron, et al. · Urologic Oncology Seminars and Original Investigations · 1
Works count: 54
Citation count: 786
H-index: 10
I10-index: 10
Year
Topic
Type